Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Net Income: 2019-2024

Historic Net Income for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to -$9.7 million.

  • Fulcrum Therapeutics' Net Income rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 321.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
  • Fulcrum Therapeutics' Net Income amounted to -$9.7 million in FY2024, which was up 90.01% from -$97.3 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Net Income ranged from a high of -$9.7 million in FY2024 and a low of -$109.9 million during FY2022.
  • For the 3-year period, Fulcrum Therapeutics' Net Income averaged around -$72.3 million, with its median value being -$97.3 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 35.90% in 2022, then skyrocketed by 90.01% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Net Income (Yearly) stood at -$70.8 million in 2020, then fell by 14.16% to -$80.8 million in 2021, then tumbled by 35.90% to -$109.9 million in 2022, then climbed by 11.41% to -$97.3 million in 2023, then surged by 90.01% to -$9.7 million in 2024.